SLV339 ( DrugBank: - )


1 disease
告示番号疾患名(ページ内リンク)臨床試験数
298遺伝性膵炎6

298. 遺伝性膵炎


臨床試験数 : 95 薬物数 : 148 - (DrugBank : 51) / 標的遺伝子数 : 53 - 標的パスウェイ数 : 142
No.TrialIDDate_
enrollment
Date_
registration
Public_titleScientific_titleConditionInterventionPrimary_
sponsor
Secondary_
sponsor
Recruitment_
Status
Inclusion_
agemin
Inclusion_
agemax
Inclusion_
gender
Target_
size
PhaseCountries
1EUCTR2007-000375-42-HU
(EUCTR)
07/04/200814/12/2007A multi-center, double-blind, parallel-design, randomized,placebo-controlled, dose-ranging study to assess the efficacy andsafety of oral recombinant microbial lipase (SLV339) in subjectswith pancreatic exocrine insufficiency due to chronic pancreatitisA multi-center, double-blind, parallel-design, randomized,placebo-controlled, dose-ranging study to assess the efficacy andsafety of oral recombinant microbial lipase (SLV339) in subjectswith pancreatic exocrine insufficiency due to chronic pancreatitis Pancreatic exocrine insufficiency due to chronic pancreatitis
MedDRA version: 9.1;Level: LLT;Classification code 10009093;Term: Chronic pancreatitis
Product Name: Recombinant microbial lipase
Product Code: SLV339
Solvay Pharmaceuticals GmbHNULLNot RecruitingFemale: yes
Male: yes
112Hungary;Czech Republic;Denmark;Latvia;Sweden
2EUCTR2007-000375-42-DK
(EUCTR)
21/02/200823/10/2007A multi-center, double-blind, parallel-design, randomized,placebo-controlled, dose-ranging study to assess the efficacy andsafety of oral recombinant microbial lipase (SLV339) in subjectswith pancreatic exocrine insufficiency due to chronic pancreatitisA multi-center, double-blind, parallel-design, randomized,placebo-controlled, dose-ranging study to assess the efficacy andsafety of oral recombinant microbial lipase (SLV339) in subjectswith pancreatic exocrine insufficiency due to chronic pancreatitis Pancreatic exocrine insufficiency due to chronic pancreatitis
MedDRA version: 9.1;Level: LLT;Classification code 10009093;Term: Chronic pancreatitis
Product Name: Recombinant microbial lipase
Product Code: SLV339
Solvay Pharmaceuticals GmbHNULLNot RecruitingFemale: yes
Male: yes
80Hungary;Czech Republic;Denmark;Latvia;Sweden
3EUCTR2007-000375-42-CZ
(EUCTR)
08/02/200817/12/2007A multi-center, double-blind, parallel-design, randomized,placebo-controlled, dose-ranging study to assess the efficacy andsafety of oral recombinant microbial lipase (SLV339) in subjectswith pancreatic exocrine insufficiency due to chronic pancreatitisA multi-center, double-blind, parallel-design, randomized,placebo-controlled, dose-ranging study to assess the efficacy andsafety of oral recombinant microbial lipase (SLV339) in subjectswith pancreatic exocrine insufficiency due to chronic pancreatitis Pancreatic exocrine insufficiency due to chronic pancreatitis
MedDRA version: 9.1;Level: LLT;Classification code 10009093;Term: Chronic pancreatitis
Product Name: Recombinant microbial lipase
Product Code: SLV339
Solvay Pharmaceuticals GmbHNULLNot RecruitingFemale: yes
Male: yes
80Hungary;Czech Republic;Denmark;Latvia;Sweden
4EUCTR2007-000375-42-LV
(EUCTR)
05/02/200812/02/2008A multi-center, double-blind, parallel-design, randomized,placebo-controlled, dose-ranging study to assess the efficacy andsafety of oral recombinant microbial lipase (SLV339) in subjectswith pancreatic exocrine insufficiency due to chronic pancreatitisA multi-center, double-blind, parallel-design, randomized,placebo-controlled, dose-ranging study to assess the efficacy andsafety of oral recombinant microbial lipase (SLV339) in subjectswith pancreatic exocrine insufficiency due to chronic pancreatitis Pancreatic exocrine insufficiency due to chronic pancreatitis
MedDRA version: 9.1;Level: LLT;Classification code 10009093;Term: Chronic pancreatitis
Product Name: Recombinant microbial lipase
Product Code: SLV339
Solvay Pharmaceuticals GmbHNULLNot RecruitingFemale: yes
Male: yes
80Hungary;Czech Republic;Denmark;Latvia;Sweden
5NCT00630279
(ClinicalTrials.gov)
February 200822/2/2008Dose-ranging Study to Evaluate Efficacy of SLV339 in Pancreatic Exocrine Insufficiency Due to Chronic PancreatitisA Multi-center, Single-blind, Parallel-design, Randomized, Placebo-controlled, Dose-ranging Study to Evaluate Oral Recombinant Microbial Lipase Efficacy in Patients With Pancreatic Exocrine Insufficiency Due to Chronic PancreatitisPancreatic Exocrine Insufficiency Due to Chronic PancreatitisDrug: Placebo;Drug: Recombinant Microbial Lipase SLV339Solvay PharmaceuticalsNULLTerminated18 YearsN/ABoth56Phase 2Czech Republic;Denmark;Hungary;Latvia;Poland;Russian Federation;Sweden
6EUCTR2007-000375-42-SE
(EUCTR)
21/12/200726/10/2007A multi-center, double-blind, parallel-design, randomized,placebo-controlled, dose-ranging study to assess the efficacy andsafety of oral recombinant microbial lipase (SLV339) in subjectswith pancreatic exocrine insufficiency due to chronic pancreatitisA multi-center, double-blind, parallel-design, randomized,placebo-controlled, dose-ranging study to assess the efficacy andsafety of oral recombinant microbial lipase (SLV339) in subjectswith pancreatic exocrine insufficiency due to chronic pancreatitis Pancreatic exocrine insufficiency due to chronic pancreatitis
MedDRA version: 9.1;Level: LLT;Classification code 10009093;Term: Chronic pancreatitis
Product Name: Recombinant microbial lipase
Product Code: SLV339
Solvay Pharmaceuticals GmbHNULLNot RecruitingFemale: yes
Male: yes
80Hungary;Czech Republic;Denmark;Latvia;Sweden